SCHEMBL6611082

SCHEMBL6611082

C=C(C(=O)OC)N(Cc1ccccc1NC(=O)c1ccsc1)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
KEAP1 Q14145 3/20 0.40
KDM4E B2RXH2 3/20 0.40
NCOR2 Q9Y618 2/20 0.40
F10 P00742 1/20 0.40
POLB P06746 1/20 0.40
GRK2 P25098 1/20 0.40
PPARG P37231 1/20 0.40
KMT2A Q03164 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40
CXCR3 P49682 2/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
TAS2R14 Q9NYV8 5/20 0.39
NFE2L2 Q16236 1/20 0.39
PTGES O14684 1/20 0.39
TAS2R8 Q9NYW2 1/20 0.39
GRM4 Q14833 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656436 0.89 LMNA (0.48) LMNAMAPTKEAP1KDM4ENCOR2
SCHEMBL6609938 0.86 MAPT (0.48) LMNAMAPTKEAP1KDM4ENCOR2
SCHEMBL6610090 0.86 SNCA (0.47) LMNAMAPTKEAP1KDM4ENCOR2
SCHEMBL7225293 0.85 ALDH1A1 (0.49) LMNAMAPTKEAP1KDM4EKMT2A
SCHEMBL5656058 0.84 POLB (0.48) MAPTKEAP1KDM4ENCOR2POLB
SCHEMBL6612494 0.83 TAS2R14 (0.46) LMNAMAPTKDM4EKMT2ATAS2R14
SCHEMBL6608937 0.83 MEN1 (0.47) LMNAMAPTKDM4ENCOR2POLB
SCHEMBL6610253 0.83 ABCB1 (0.51) LMNAMAPTKDM4EPOLBKMT2A
SCHEMBL6610841 0.82 KEAP1 (0.48) KEAP1KDM4ENCOR2POLBGRK2
SCHEMBL6610937 0.82 POLB (0.48) LMNAMAPTKEAP1KDM4ENCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed